Drug Patent Watch

DECEMBER 30, 2024

The regulatory environment in Japan for generic drug development is complex and has undergone significant changes in recent years. Abbreviated New Drug Application (ANDA) : Required for marketing approval of generic drugs. Regulatory System on Generic Drugs in Japan.

Generic Drugs 52

Generic Drugs Bioequivalency Development Drugs 52

Drug Patent Watch

OCTOBER 14, 2024

Risk assessment plays a crucial role in the development of generic drugs, ensuring that these products meet the required standards of safety and efficacy.

Generic Drugs 111

Generic Drugs Development Drugs Branding 111

Drug Patent Watch

DECEMBER 10, 2024

Generic drug development is a complex process that involves not only scientific and medical expertise but also adherence to strict legal and ethical standards. Scientific expertise plays a crucial role in ensuring that generic drugs are held to the same standards of quality, safety, and efficacy as their brand-name counterparts.

Generic Drugs 98

Generic Drugs Bioequivalency Development Drugs 98

Drug Patent Watch

JUNE 18, 2024

Branded generics are generic drugs that are marketed under a brand name by the manufacturer. These products contain the same active ingredients as their brand-name counterparts but are typically sold at a lower price point.

Branding 105

Branding Generic Drugs Containment Manufacturing 105

Pharmaceutical Technology

MAY 3, 2023

Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. These medicines comprise about 10% of all generics approved each year. Still, the FDA does prioritize the review of submissions for first generics.

Generic Drugs 246

Generic Drugs Branding Drugs Production 246

Pharmaceutical Technology

JULY 25, 2022

But this also reflects a wider trend within the broader market, which is moving towards complex biological and non-biological products, he adds. Broadly, complex drugs are treatments with complicated active pharmaceutical ingredients (APIs), formulations, or drug/device combinations.

Drugs 298

Drugs Manufacturing Production Marketing 298

Pharmaceutical Technology

JULY 15, 2022

California’s budget documents give few details about the tender process, but state that CalRx will spend $50 million to partner with a contract manufacturer to develop biosimilar insulin products in vial and pen form. This CMO will be responsible for product roll-out and distribution. In-house manufacturing the norm.

Insulin 328

Insulin Manufacturing Contract Manufacturing Production 328

Pharmacy Checkers

FEBRUARY 5, 2021

The Rand Corporation has released an impressive study showing that brand name drugs cost far more in the United States than in other countries – on average 344% more. For those of you looking for a methodologically strong analysis of international drug prices and a history of related studies, this is the report for you.

Branding 97

Branding Drugs Sales Generic Drugs 97

NY Times

SEPTEMBER 18, 2021

Competition for market share at rock-bottom prices has led to shortages, price-spikes, allegations of price-fixing, and substandard and even dangerous practices.

Generic Drugs 96

Generic Drugs Drugs Marketing Branding 96

Drug Patent Watch

JANUARY 13, 2025

Unlike traditional generic drugs, biosimilars face a more complex regulatory pathway and manufacturing process, which influences their market entry and adoption rates. Misconceptions about the efficacy and safety of biosimilars can lead to hesitancy in prescribing or using these products.

Marketing 78

Marketing Insulin Generic Drugs Medicine 78

World of DTC Marketing

AUGUST 7, 2022

Once limited to a few new treatments, it’s now being applied widely, even to generic drugs and established regimens.?The Medicare drug insurance is a product of compromise after decades of debate in Congress. Generic drugs may also be cheaper with a coupon than your drug insurance. The result:?

Doctors 263

Doctors Doctor Generic Drugs Drugs 263

Pharmaceutical Technology

OCTOBER 5, 2008

’ Generic drug renaissance Shionogi’s acquisition of Sciele was partly due to the US business experience of Shionogi’s chief executive, Isao Teshirogi. ” The move, which came in June, also gives Japanese drugs maker Daiichi Sankyo a foothold in the Indian market through Ranbaxy’s location. .”

Generic Drugs 100

Generic Drugs Marketing Branding Drugs 100

STAT News

MARCH 16, 2023

regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over a recent 15-year period, but a new study found that generic companies have only twice successfully pursued an established pathway to create lower-cost, rival products.

Generic Drugs 105

Generic Drugs Branding Regulation Manufacturing 105

XTalks

FEBRUARY 8, 2021

While the approval pathway for biosimilar products was established 12 years ago, there are still misconceptions about how biosimilars are approved, biosimilarity versus interchangeable status and which patients can be treated with biosimilars. Biosimilars are the “generic” drugs of the biopharma world. What is a Biosimilar?

Production 78

Production Insulin Branding Generic Drugs 78

Drug Channels

OCTOBER 18, 2022

The biosimilar boom for provider-administered drugs continues to accelerate. Some major biological reference products have now lost a majority of their unit sales to their biosimilars. Below, we share our estimates for wholesalers’ gross margins for brand-name, generic, and biosimilar drugs. drug distribution.

Drugs 97

Drugs Generic Drugs Branding Sales 97

Pharmaceutical Technology

OCTOBER 28, 2022

According to Dr Mansoor Amiji of Northeastern University: “Instead of relying on product quality as a readout after the product is made, you start to implement these procedures into the product production processes. Practising QbD in biosimilar product development.

Bioequivalency 130

Bioequivalency Production Contamination Branding 130

Pharmaceutical Technology

DECEMBER 4, 2022

Citing studies comparing such products, there are no important differences between biosimilars and their branded counterpart, says Arnold Vulto, PharmD, professor of hospital pharmacy at Erasmus University, Rotterdam. Product variation creates patient uncertainty. However, there tend to be some differences between the products.

Marketing 262

Marketing Pharmacy Production Branding 262

XTalks

JANUARY 20, 2025

This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

Pharmaceutical Technology

SEPTEMBER 15, 2022

Various factors have contributed to the need and growth of API chemical suppliers such as rising healthcare expenditure, increasing disposable incomes, growing geriatric population, increasing incidence of chronic diseases, patent expiration of blockbuster drugs, increased consumption of generic drugs, and intervention of the new generation APIs.

Marketing 100

Marketing Manufacturing Generic Drugs Containment 100

Pharmacy Checkers

FEBRUARY 14, 2020

Years ago, they took on the Food and Drug Administration in regards to Budeprion XL distributed by Teva Pharmaceuticals, the supposed generic equivalent to the popular antidepressant, Wellbutrin XL. Many readers complained that it just wasn’t cutting it compared to the brand name version. Just switch back to the brand!”

Branding 62

Branding FDA Approval Pharmacy Bioequivalency 62

XTalks

MARCH 15, 2024

Lilly’s move is a significant shift in strategy as drugmakers have traditionally steered clear of delivering products to people’s homes or connecting them with healthcare providers. It is estimated that more than 8 million Americans rely on insulin products to manage their diabetes. More than 40 percent of Americans are obese.

Pharmacy 111

Pharmacy Drugs Insulin Branding 111

FDA Law Blog

NOVEMBER 16, 2021

That section of the bill – along with the other accompanying sections and parts of the bill – would amend Title XI of the Social Security Act to create a new part – Part E – requiring the HHS Secretary to establish a “Fair Price Negotiation Program” intended to lower prices for certain high-priced single-source drugs and biological products.

Generic Drugs 52

Generic Drugs Manufacturing Drugs Licensing 52

The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. for the treatment of diabetes. Biosimilars marketed in the U.S.

Insulin 52

Insulin Production FDA Approval Generic Drugs 52

pharmaphorum

JULY 29, 2021

Generic drugmaker Mylan has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi’s once-daily insulin Lantus.

Insulin 98

Insulin Drugs Production Generic Drugs 98

The Pharma Data

MARCH 15, 2022

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks. Today, the U.S.

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

Pharmaceutical Technology

FEBRUARY 24, 2023

A leaked draft (see below) of the legislation, whose final version will be published next month, proposes reducing market exclusivity time by one year for most branded drugs, although it would extend exclusivity for certain drugs for unmet needs.

Regulation 162

Regulation Clinical Trials Clinical Trials Medicine 162

Pharmacy Checkers

MAY 22, 2020

PharmacyChecker pays close attention and has performed considerable research related to where drugs are made. Most notably, by researching drug labels and contacting drug companies, we found that 71% of brand name drugs sold in the U.S. has proved itself to be too dependent on drug imports from China.

Manufacturing 98

Manufacturing Drugs Generic Drugs Branding 98

Pharmaceutical Technology

JANUARY 6, 2023

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Gilenya legal drama.

Doctor 242

Doctor Doctors Drugs Sales 242

Druggist

SEPTEMBER 30, 2020

(video) Buscopan vs Mebeverine: mechanism of action and symptoms control Although used in the symptomatic treatment of the same condition, Buscopan and mebeverine are not the same drugs. Buscopan is a brand name for a drug called hyoscine butylbromide. Both products contain the same drug – hyoscine butylbromide.

Pharmacy 98

Pharmacy Containment Drugs Branding 98

Pharmacy Checkers

NOVEMBER 21, 2019

So, without further ado, a moment of praise amongst the criticism: Despite its inability to please everyone, the FDA protects, lengthens, and improves the quality of hundreds of millions of lives through its work regulating the development, creation and distribution of medical products. The medications that we obtain in the U.S., Far from it.

Generic Drugs 68

Generic Drugs Manufacturing Drugs Regulation 68

pharmaphorum

NOVEMBER 2, 2020

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products. Mylan meanwhile will benefit from Upjohn’s greater global reach, allowing its generics to grow more quickly, according to the companies.

Generic Drugs 52

Generic Drugs Contract Manufacturing Production Manufacturing 52

XTalks

JUNE 8, 2022

Novartis’ biosimilars and generics drug division Sandoz has announced a new global campaign called ‘Act4Biosimilars’ to help raise awareness about biosimilars and increase their adoption by at least 30 percent in over 30 countries by the year 2030. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.

Generic Pharmaceutical 69

Generic Pharmaceutical Production Medicine Branding 69

Pharmacy Checkers

JANUARY 10, 2020

A friend of mine, who has very difficult to control cholesterol, was prescribed Livalo, an FDA-approved brand of the drug pitavastatin. He went to our site to discover that brand-name Livalo ( pitavastatin ). He went to our site to discover that brand-name Livalo ( pitavastatin ). Is the drug safe?

FDA Approval 62

FDA Approval Branding Pharmacy Manufacturing 62

FDA Law Blog

SEPTEMBER 19, 2023

The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. But whether a patent that only claims a device constituent of a combination product, however, was not addressed.

Drugs 105

Drugs Branding Drug Delivery Systems Generic Drugs 105

Pharmacy Checkers

SEPTEMBER 10, 2020

Because they don’t do adequate testing to prove safety and effectiveness of drugs. Furthermore, the agency’s position that FDA-approved generic drugs work just as well as the brand is often not true. Indeed, according to Valisure, not all FDA-approved generic versions of brand drugs are created equal.

Drugs 61

Drugs FDA Approval Generic Drugs Branding 61

FDA Law Blog

SEPTEMBER 15, 2024

IPRs have become an important tool used by generic drug and biosimilar manufacturers to try and clear patent thickets covering brand-name products prior to or during the pendency of an ANDA or aBLA submission. Reading through the “Findings” section of S. But as AAM notes in a March 2024 letter opposing S.

Production 76

Production Branding Generic Drugs Drugs 76

Pharma in Brief

NOVEMBER 5, 2023

Background A manufacturer can apply to have a drug product listed on Ontario’s Formulary for coverage under the Ontario Drug Benefit ( ODB ) program. For a generic or biosimilar product, the manufacturer may also apply to have the drug product designated on the Formulary as interchangeable with the original brand product.

Drugs 52

Drugs Regulation Production Generic Drugs 52